Specifically, for individuals with established atherosclerotic CVD or comorbid CKD, combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists could be used to further reduce cardiovascular events. Here, SLC5A2 is linked to chronic kidney disease.